This page provides a timely snapshot of our most recent negotiation activity, including an overview of open files and updates on key milestones from the past 4 weeks.
How current is this information?
The content on this page is updated on an ongoing basis to reflect the most recent available information. Please note that updates about negotiation activity may take 1–2 weeks to be processed.
“Under consideration for negotiation” means we’re currently considering the evidence and gathering other information to inform the negotiation approach, including the drug’s eligibility for expedited negotiation pathways. Once negotiation activities are underway, the drug is in active negotiation.
Letters of engagement
We send letters of engagement (LOE) to manufacturers at the end of the consideration phase, to begin active negotiations. The drugs listed below have recently entered active negotiation.
| Brand name | Manufacturer | Indication | LOE date |
|---|---|---|---|
| Tecentriq | Hoffmann-La Roche Ltd. | Zepzelca, in combination with atezolizumab, for the first-line maintenance treatment of extensive-stage small cell lung cancer in adult patients whose disease has not progressed following induction therapy with atezolizumab, carboplatin and etoposide |
2026-10-20 |
| Zepzelca | Jazz Pharmaceuticals Canada Inc. | In combination with atezolizumab, for the first-line maintenance treatment of extensive-stage small cell lung cancer in adult patients whose disease has not progressed following induction therapy with atezolizumab, carboplatin and etoposide. | 2026-10-20 |
| Vyvgart | Argenx Canada Inc. | Generalized myasthenia gravis (gMG) | 2026-11-04 |
| Litfulo | Pfizer Canada ULC | For the treatment of adults and adolescents 12 years and older with severe alopecia areata | 2026-11-04 |
Letters of intent
A letter of intent (LOI) outlines the negotiated terms of an agreement between the pCPA and a manufacturer at the end of a successful negotiation. The list below reflects our latest LOIs.
| Title | Manufacturer | Indication | LOE date | LOI date |
|---|---|---|---|---|
| Rybrevant SC | Janssen Inc. | Multiple Indications | 2026-11-16 | |
| Elahere | AbbVie Corporation | For the treatment of adults with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens | 2026-09-23 | 2026-10-20 |
| Keytruda | Merck Canada Inc. | For the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by a validated test, and who have received one or two prior systemic treatment regimens | 2026-07-06 | 2026-10-28 |
| TBC (ranibizumab) | Sandoz Canada Inc. | Neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy | 2026-06-17 | 2026-11-11 |
| Tezspire | AstraZeneca Canada Inc. | As an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery | 2026-07-21 | 2026-11-09 |
| Tolak | Actinic keratosis | 2026-09-09 | 2026-11-13 | |
| Rinvoq | AbbVie Corporation | Giant Cell Arteritis | 2026-04-13 | 2026-10-26 |
| Odensify | Jamp Pharma Corporation | Multiple Indications | 2026-07-16 | 2026-10-27 |
| Xdeno | Jamp Pharma Corporation | Multiple Indications | 2026-07-16 | 2026-10-27 |
| Elfabrio | Chiesi Canada Corporation | Fabry Disease | 2026-06-09 | 2026-10-30 |
| Sarclisa | Sanofi Genzyme Canada | In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). | 2026-02-20 | 2026-11-09 |
Negotiations ended without agreement
Both negotiating parties strive to reach timely agreements. In rare cases, alignment between manufacturers and the pCPA can’t be reached. Each negotiation is unique, and decisions are made based on the information available at the time.
The pCPA always welcomes unsolicited offers, should a manufacturer want to re-engage and go back to the negotiation table.
When agreements can’t be reached, public drug plans may make decisions about providing coverage through their exceptional access programs.
| Title | Manufacturer | Indication | LOE date | Close date |
|---|---|---|---|---|
| Talvey (Active ENP) | Janssen Inc. | For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy. | 2026-07-28 | 2026-10-23 |
| Jatenzo | Tolmar Pharmaceuticals Canada, Inc. | Testosterone replacement therapy | 2026-07-27 | 2026-10-22 |
| Isturisa | Recordati Rare Diseases Canada Inc. | For the treatment of adult patients with Cushing's disease who have persistent or recurrent hypercortisolism after primary pituitary surgery and/or irradiation, or for whom pituitary surgery is not an option. | 2026-04-28 | 2026-10-22 |
Negotiations that weren’t pursued - Last 4 weeks
We don’t pursue negotiations in cases where the drug’s health technology assessment (HTA) recommendations were negative or “do not reimburse.” Other reasons, such as the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected on the drug’s page in the database.
There have been no negotiations which pCPA decided not to pursue in the last four weeks